Bristol Shifts Early R&D Focus With iPierian Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma adds a neurodegenerative asset to its early stage pipeline with the $175 million acquisition of iPierian; the firm will begin with studying the drug in a rare genetic disorder.